Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis

European Journal of Neurology

Volumn 7, Issue 3, 2000, Pages 281-289

  Sellebjerg, F ^a   Christiansen, M ^a   Jensen, J ^a   Frederiksen, J L ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cerebrospinal fluid immunology; Methylprednisolone; Multiple sclerosis; Optic neuritis; T cell immunology

Indexed keywords

ALBUMIN; CD4 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; GELATINASE B; HLA DR ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 2 RECEPTOR; METHYLPREDNISOLONE; MYELIN BASIC PROTEIN; PLACEBO; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; INFLAMMATORY CELL; LEUKOCYTE COUNT; LUMBAR PUNCTURE; MALE; MULTIPLE SCLEROSIS; OPTIC NERVE DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNE SYSTEM; IMMUNOGLOBULIN G; LEUKOCYTE COUNT; MALE; MATRIX METALLOPROTEINASE 9; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; OPTIC NEURITIS; RANDOMIZED CONTROLLED TRIALS; SPINAL CORD; SPINAL PUNCTURE; TRANSFORMING GROWTH FACTOR BETA;

EID: 0034465872     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2000.00074.x     Document Type: Article

References (63)

1. Methylprednisolone in multiple sclerosis: A comparison of oral with intravenous therapy at equivalent high dose
2. Methylprednisolone in multiple sclerosis exacerbation: Changes in CSF parameters
3. Glucocorticosteroid therapy for multiple sclerosis: A critical review
4. Molecules associated with human Th1 and Th2 cells
5. Regulation of transforming growth factor-beta1 gene expression by glucocorticoids in normal human T lymphocytes
6. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis
7. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone
8. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis
9. TGF-beta-like activity produced during regression of exacerbations in multiple sclerosis
10. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis
11. Glucocorticosteroid action on the immune system: Molecular and cellular aspects
12. Possible role of transforming growth factor-beta in relapsing-remitting multiple sclerosis
13. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results
14. Isolation and characterization of autoreactive proteolipid protein-peptide specific T-cell clones from multiple sclerosis patients
15. Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects
16. Transient immunomodulation by intravenous methylprednisolone treatment of multiple sclerosis
17. Effects of intravenous methylprednisolone therapy on leukocyte and soluble adhesion molecule expression in MS
18. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis
19. CD8+ high CD11b+ low T cells (T suppressor-effectors) in multiple sclerosis cerebrospinal fluid are increased during high dose corticosteroid treatment
20. Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS
21. Tumor necrosis factor-alfa and its soluble receptors in plasma and cerebrospinal fluid of multiple sclerosis patients treated with methylprednisolone
22. HLA-DR antigen expression on T cells from cerebrospinal fluid in multiple sclerosis and aseptic meningo-encephalitis
23. CSF neopterin as marker of disease activity in multiple sclerosis
24. CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone
25. T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolone
26. Follow-up study of MS patients treated with high-dose intravenous methylprednisolone
27. Effect of high-dose steroid therapy on T-cell subpopulations. A longitudinal study in MS patients
28. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse
29. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory disorders
30. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis
31. Immune response-associated production of neopterin
32. The effect of methylprednisolone on lymphocyte phenotype and function in patients with multiple sclerosis
33. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
34. Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses
35. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis
36. The expression of integrins on activated T-cells in multiple sclerosis. Effect of intravenous methylprednisolone treatment
37. Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts
38. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects
39. Defective production of anti-inflammatory cytokine, TGF-beta by T cell lines of patients with active multiple sclerosis
40. Influx of nonactivated T lymphocytes into the cerebrospinal fluid during relapse of multiple sclerosis
41. Corticosteroids induce expression of transforming-growth-factor-beta1 mRNA in peripheral blood mononuclear cells of patients with multiple sclerosis
42. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis
43. Comparison of the effects of oral versus intravenous methylprednisolone regimens on peripheral blood T lymphocyte adhesion molecule expression, T cell subsets distribution and TNF alpha concentrations in multiple sclerosis
44. Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4 + T cell clones
45. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis
46. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity
47. Biologically active TGF-beta1 is increased in cerebrospinal fluid while it is reduced in serum in multiple sclerosis patients
48. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury
49. Etiology and pathogenesis of multiple sclerosis
50. Qualitative assessment of intrathecal IgG synthesis by isoelectric focusing and immunodetection: Interlaboratory reproducibility and interobserver agreement
51. The cerebrospinal fluid in multiple sclerosis. Quantitative assessment of intrathecal immunoglobulin synthesis by empirical formulae
52. Cytokines and soluble IL-4 receptors in patients with acute optic neuritis and multiple sclerosis
53. Cerebrospinal fluid measures of disease activity in multiple sclerosis
54. A double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS
55. Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis
56. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis
57. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis
58. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis
59. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9
60. Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis
61. Effect of high-dose methylprednisolone on immune functions in multiple sclerosis patients
62. Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbations
63. Matrix metalloproteinases and diseases of the CNS